menu
    • menu

    Company profile for Veru

    NEW Drugs in Dev: 6
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer. The Company’s prostate cancer pipeline includes VERU-111, Zuclomiphene citrate and VERU-100. VERU-111 is an oral, next-generation, first-in-class small molecule that targets and disrupts alpha and beta tubulin subunits of microtubules in cells to treat metastatic prostate cancer pat...
    Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer. The Company’s prostate cancer pipeline includes VERU-111, Zuclomiphene citrate and VERU-100. VERU-111 is an oral, next-generation, first-in-class small molecule that targets and disrupts alpha and beta tubulin subunits of microtubules in cells to treat metastatic prostate cancer patients whose disease is resistant to both castration and novel androgen blocking agents (abiraterone or enzalutamide).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VeruUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    48 NW 25th St. Suite 102 Miami, FL 33127
    Telephone
    Telephone
    1-305-509-6897
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://verupharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/740437/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Veru_Pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Veru Enrolls 1st Patient In Trial For Enobosarm & Semaglutide
    Veru Enrolls 1st Patient In Trial For Enobosarm & Semaglutide

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251811/11676/en/Veru-Enrolls-First-Patient-in-Phase-2b-PLATEAU-Clinical-Trial-of-Enobosarm-and-Semaglutide-Combination-for-High-Quality-Weight-Loss.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Veru To Present At Oppenheimer Healthcare Life Sciences
    Veru To Present At Oppenheimer Healthcare Life Sciences

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3241118/11676/en/Veru-to-Present-at-the-Oppenheimer-36th-Annual-Healthcare-Life-Sciences-Conference.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share
    Veru Unveils Fiscal Q1 2026 Financials And Clinical Advances
    Veru Unveils Fiscal Q1 2026 Financials And Clinical Advances

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236088/11676/en/Veru-Reports-Fiscal-2026-First-Quarter-Financial-Results-and-Clinical-Program-Progress.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    Veru To Report Q1 Fiscal 2026 Financial Results On Feb 11
    Veru To Report Q1 Fiscal 2026 Financial Results On Feb 11

    04 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/04/3232036/11676/en/Veru-to-Report-Fiscal-2026-First-Quarter-Financial-Results-on-February-11th.html

    GLOBENEWSWIRE
    04 Feb 2026
    Share Share
    Veru Unveils Fy2025 Financials And Clinical Program Advancements
    Veru Unveils Fy2025 Financials And Clinical Program Advancements

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3206825/11676/en/Veru-Reports-Fiscal-Year-2025-Financial-Results-and-Clinical-Program-Progress.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Veru Reports Fiscal 2025 Financial Results Dec. 17
    Veru Reports Fiscal 2025 Financial Results Dec. 17

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203161/11676/en/Veru-to-Report-Fiscal-Year-2025-Financial-Results-on-December-17th.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search